The Latest Analyst Ratings for Bio-Rad Laboratories
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 4 analysts have published their opinion on Bio-Rad Laboratories (NYSE:BIO) stock. The company has an average price target of $539.0, a decrease from the previous average price target of $570.67. The analysts' ratings are mostly bullish.
August 04, 2023 | 3:32 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Bio-Rad Laboratories has received mostly bullish ratings from analysts, but the average price target has decreased.
The bullish ratings indicate a positive outlook for the company. However, the decrease in the average price target could potentially indicate a lower expected return, which might impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100